ARA-290 Peptide

Description

ARA-290 is a synthetic 11-amino-acid peptide derived from the tissue-protective region of erythropoietin (EPO). Researchers developed ARA-290 to investigate EPO-related tissue-protective signaling without the primary erythropoietic activity associated with conventional EPO.

Preclinical research has examined ARA-290 in areas including cellular protection, inflammation, vascular biology, nerve-related research, and tissue response.

Ion Peptides Solution offers ARA-290 for laboratory and scientific research. This product is not marketed as an approved treatment or medication.

Buy ARA-290

Researchers looking to buy ARA-290 can source this peptide from Ion Peptides Solution for qualified laboratory research.

ARA-290 remains an investigational research compound. Researchers should follow appropriate laboratory procedures and applicable regulations when handling peptide materials.

What Is ARA-290?

ARA-290, also known as cibinetide, is a synthetic peptide designed around the tissue-protective signaling properties associated with erythropoietin. Research describes ARA-290 as a selective agonist of the erythropoietin receptor/CD131 heteroreceptor complex.

Unlike conventional EPO, researchers designed ARA-290 to focus on non-erythropoietic signaling. Studies have therefore investigated its potential role in tissue-protection and cellular-response pathways without directly targeting the conventional red-blood-cell production pathway.

Uses & Potential Research Benefits

Researchers have investigated ARA-290 across several areas of preclinical science, including:

• Neurobiology research: Scientists study ARA-290 in models involving neuronal survival and nerve-related pathways.
• Cellular protection: Research examines signaling pathways associated with cellular survival and protection.
• Inflammation research: Researchers investigate its interaction with inflammatory and immune-response pathways.
• Vascular research: Studies have examined ARA-290’s effects on endothelial progenitor cells and angiogenic activity.
• Tissue-response research: Researchers investigate its potential influence on tissue-protective mechanisms.
• Ischemia research: Preclinical models have examined ARA-290 in ischemic tissue and vascular-response settings.
• Cell-signaling research: Scientists study pathways associated with the erythropoietin/CD131 receptor system.

These research areas describe experimental findings and should not be interpreted as proven medical benefits.

Specifications

• Product: ARA-290
• Alternative Name: Cibinetide
• Type: Synthetic peptide
• Peptide Length: 11 amino acids
• Research Category: Erythropoietin-derived peptide
• Primary Research Area: Tissue-protective and cellular signaling research
• Intended Use: Laboratory and scientific research
• Human Use: Not approved as a general human therapeutic
• Veterinary Use: Not intended for veterinary use

Key Features

• Synthetic 11-amino-acid peptide
• Derived from erythropoietin-related tissue-protective structure
• Researches non-erythropoietic signaling
• Studied in cellular, vascular, neurological, and tissue-response models
• Suitable for controlled laboratory research
• Research-use-only product

FAQs

What is ARA-290?

ARA-290 is a synthetic 11-amino-acid peptide also known as cibinetide. Researchers study it as a non-erythropoietic peptide associated with erythropoietin-related tissue-protective signaling.

What is ARA-290 used for?

Researchers study ARA-290 in areas such as cellular protection, neurological research, vascular biology, inflammation, and tissue-response pathways.

Is ARA-290 the same as erythropoietin?

No. ARA-290 is a much smaller synthetic peptide designed to investigate selected tissue-protective signaling associated with EPO. It does not represent recombinant erythropoietin.

What is another name for ARA-290?

ARA-290 is also known as cibinetide.

Is ARA-290 a research peptide?

Yes. Researchers have investigated ARA-290 in preclinical and clinical research settings, but research status does not mean that it has general approval as a therapeutic product.

Does ARA-290 have an established human dosage?

There is no general approved human dosage for routine use. Experimental protocols can use different parameters depending on the research design.

Can I buy ARA-290 from Ion Peptides Solution?

Ion Peptides Solution offers ARA-290 as a research-use product for qualified laboratory applications.

What receptor does ARA-290 target?

Research identifies ARA-290 as an agonist of the erythropoietin receptor/CD131 heteroreceptor complex, a signaling system associated with tissue-protective effects.

Why Buy ARA-290 From Ion Peptides Solution?

Ion Peptides Solution focuses on research-oriented peptide products for laboratory and scientific applications.

When you buy ARA-290, you can use the product for appropriate laboratory research involving peptide signaling, cellular biology, tissue-response pathways, and related experimental models.

We provide clear product information while maintaining a research-use-only focus.

For research use only. Not for human or veterinary consumption.